The Lung HIV Microbiome Project (LHMP) - Catalog
-
Name
The Lung HIV Microbiome Project (LHMP)
-
Accession Number
HLB01951515a
-
Acronym
LHMP
-
Related studies
-
BSI Study IDs
LHMP
-
Is public use dataset
False
-
Keywords
-
Ingestion Status---------
-
Has Study Datasets
False
-
Has Specimens
True
-
Specimen ID TypeCoded
-
Study Website
https://biostatcenter.gwu.edu/?pkey=54
-
The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.
False
-
Clinical Trial URLsN/A
-
Study typeEpidemiology Study
-
Collection TypeOpen BioLINCC Study
-
Cohort typeAdult
-
Interventions
-
Study Open Date (Data)
None
-
Study Open Date (Specimens)
2015-10-12
-
Date materials available
2015-10-08
-
Last updated
None
-
Study period
October 2009 – November 2015
-
Study Contacts
-
NHLBI Division
DLD
-
ClassificationLung
-
HIV study classificationHIV
-
COVID study classificationnon-COVID
-
Pre-Website # of Specimens Shipped
0
-
# of Returned Specimens
90
-
Primary Publication URLs
N/A
-
Commercial use data restrictionsNot Applicable (Specimens Only)
-
Data restrictions based on area of researchNot Applicable (Specimens Only)
-
Commercial use specimen restrictionsNo
-
Non-genetic use specimen restrictions based on area of useYes
-
Genetic use of specimens allowed?Yes
-
Genetic use area of research restrictionsYes
-
Specific Consent Restrictions
Consent for use of biospecimens is tiered to HIV related studies or any future study.
-
ConditionsHIV-1
Lung Diseases
-
Objectives
To characterize the microbiome of the lung and respiratory tract, and enhance understanding of the role of the lung microbiome in preserving health or causing disease and in the divergent effects observed in HIV-infected versus uninfected individuals.
-
Background
The respiratory tract is constantly exposed to the external environment and serves as the portal of entry for many microbes. The characteristics and mix of organisms populating the respiratory tract, coupled with the state of local respiratory defenses are key factors in determining whether a person remains healthy or develops acute, chronic, or latent infection. Inflammation in the airways and lungs and how it progresses or is resolved affects not only local immune mediators and primary gas exchange functions, but may also have consequences for the whole immune system and the progression of diseases in other organs.
HIV-infected individuals are at high risk of developing pneumonias caused by pathogenic and opportunistic microorganisms. These respiratory infections frequently cause morbidity, are often life threatening, and may increase the rate of replication of HIV, accelerating the course of the disease. HIV-infected individuals experience a decrease in lung function following pneumonias which are not observed in normal, HIV-uninfected populations. Furthermore, lung infections and microbial colonizations are suspected in the etiology of HIV-associated emphysema and pulmonary hypertension. An increasingly important issue is that lung infections may play a role in inducing the immune reconstitution syndrome seen in some HIV-infected patients following initiation of multi-drug antiretroviral regimens.
Therefore, knowledge of the lung microbiome in healthy and diseased states may lead to the identification of predictors of disease progression and therapeutic targets for translation into better preventive and treatment strategies. The LHMP was developed as a cooperative network responsible for carrying out both joint protocols and integrating independent protocols that benefit from increased sample size. This effort was meant to provide initial data to develop further hypotheses addressing differences between HIV-infected and HIV-uninfected individuals.
-
Participants
Eligible subjects included HIV positive and HIV negative adults. Participant eligibility for the LHMP was confirmed by each center according to the parameters of their individual protocols, which may also define additional inclusion or exclusion criteria.
-
Design
The LHMP brought the distinct efforts of six clinical centers together under a single infrastructure, creating a network that combined the expertise accumulated across the range of involved disciplines in a focused and concentrated collaboration. Since multiple studies were involved in the project, the research design of each study will vary with the objective of that study. All data and samples were collected during a baseline assessment for LHMP.
-
Conclusions
-
Disease classification
-
Publications
-
Mat typesBronchial Lavage
Oral Wash (Saline)
Peripheral Blood Mononuclear Cells
Plasma
-
Network
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request.
Section 3.0 of the BioLINCC Handbook
describes the components of the review process.
-
Material Types
Last Modified: Oct. 26, 2018, 10:54 a.m. -
General Freeze/Thaw Status
-
Visits (Vials)10/26/2018
Plasma PBMC Bronchial Lavage Oral Wash Total 1 Visit Per Subject 556 52 1199 242 2049
Last Modified: Oct. 26, 2018, 10:54 a.m. -
Visits (Subjects)10/26/2018
Plasma Total number of subjects Average volume (ml) per subject 1 Visit Per Subject 140 1.22 Bronchial Lavage Total number of subjects Average volume (ml) per subject 1 Visit Per Subject 182 14.17 Oral Wash Total number of subjects Average volume (ml) per subject 1 Visit Per Subject 142 1.78 PBMC Total number of subjects Average vials per subject 1 Visit Per Subject 26.00 2.00
Last Modified: Oct. 26, 2018, 10:54 a.m.